Cellyan Biotechnology Reports Steep Decline in H1 2026 Earnings, Faces Nasdaq Delisting Threat Amidst Executive Turnover and Capital Restructuring

summarizeSummary

Cellyan Biotechnology reported a sharp decline in H1 2026 earnings and negative operating cash flow, received a Nasdaq delisting notice, and experienced significant executive and board changes, alongside a capital restructuring.

check_boxKey Events

• Significant Revenue and Profit Decline

  For the six months ended September 30, 2025, revenues decreased by 36% to $7.14 million, and net profit fell by 81% to $0.15 million, with operating cash flow turning negative at $(0.24) million.

• Nasdaq Minimum Bid Price Non-Compliance

  On January 12, 2026, the company received a notice from Nasdaq regarding non-compliance with the minimum $1.00 bid price requirement, with a deadline of July 13, 2026, to regain compliance.

• Executive and Board Turnover

  In October and November 2025, the CEO, CFO, an Executive Director, and two Independent Directors resigned. New appointments were made for CEO, CFO, Chief Strategy Officer, and an Independent Director.

• Capital Restructuring and Share Repurchase

  In December 2025, shareholders approved an amendment to authorized share capital and the repurchase of 7.15 million Class A ordinary shares for a nominal $1, funded by a concurrent private placement of 7.15 million Class B ordinary shares. This transaction was completed by February 8, 2026.

auto_awesomeAnalysis

Cellyan Biotechnology Co., Ltd (formerly Hong Kong Pharma Digital Technology Holdings Limited) reported a significant deterioration in its financial performance for the six months ended September 30, 2025, with revenues decreasing by 36% and net profit plummeting by 81% compared to the prior year. The company also experienced a shift to negative operating cash flow. Compounding these operational challenges, the company received a Nasdaq minimum bid price non-compliance notice in January 2026, putting its listing status at risk. This period also saw substantial executive and board turnover, including the resignations of the CEO, CFO, and two independent directors, followed by new appointments. Furthermore, the company undertook a significant capital restructuring in December 2025, repurchasing 7.15 million Class A ordinary shares for a nominal price and concurrently issuing 7.15 million Class B ordinary shares. While an early redemption of a $2.33 million investment provided a crucial liquidity injection, the overall picture indicates a company facing severe operational headwinds, governance changes, and an immediate threat to its public market access.